Counterfeit Drug Screening Devices Nets National Award
Technology Could Improve Health Outcomes in Developing World
By Mark Dwortzan
An estimated 50 percent of medicines distributed in developing countries are either counterfeit or significantly substandard, resulting in countless medical complications and deaths. To address this problem, Associate Professor Muhammad Zaman (BME, MSE) and Boston University graduate students Darash Desai (BME) and Andrea Fernandes (SMG, SPH) are developing PharmaCheck, a fast, portable, user-friendly detector for screening counterfeit and substandard medicines. To test a medication, a user places a pill into a small testing box which instantly reports the amount of active ingredient found in the pill.
The device’s clear potential to dramatically improve health outcomes in resource-limited countries has attracted significant funding over the past year, and now its developers have received one of nine $18,500 Entrepreneurial Team (E-Team) “Stage Two” grants from the National Collegiate Inventors and Innovators Alliance (NCIIA), which promotes technology innovation and entrepreneurship in higher education. The grant package includes an intensive workshop to help the team further develop its business strategy, followed by six monthly sessions of business coaching—and eligibility for up to $50,000 in additional funding.
“We are absolutely thrilled to receive the funding from NCIIA, which will enable our students to further develop PharmaCheck and conduct field and market research that will be absolutely critical for its long-term success and impact,” said Zaman.
Funding from the NCIIA and other agencies will support the team’s efforts to complete its first prototype; perform extensive, hands-on testing in the field in Ghana; and conduct analysis of the medicine supply chain in developing countries to pinpoint where poor-quality medicines are introduced. The team’s ultimate goal is to enable users from pharmacists to regulatory authorities to effectively and easily control the quality of medicine delivered to patients.
“Our hope is that PharmaCheck will help support and increase medicine quality testing around the world and ensure that medicines intended to save lives do just that,” said Desai. “The opportunity to work on everything from conceptual and technical development to business strategy and scale-up has been an invaluable learning experience that’s surprisingly uncommon in graduate work.”
Focused on marketing and funding for PharmaCheck, Fernandes aims to ensure that the device reaches the people it’s intended to serve.
“All of the market research data that we’ve collected indicates that there is a real need and willingness to pay for this capability,” she said. “The challenge is how to create a business model around this technology to sustain economies of scale and create impact.”
Through grants and intensive training, the NCIIA E-Team program supports the next generation of innovators striving to improve the lives of underserved populations in developing countries and meet critical social and environmental needs in the U.S. Since NCIIA’s founding in 1995, more than 180 companies have launched as a result of early-stage support from NCIIA grants and training.
More information about PharmaCheck, including a video presentation, is available here.